|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 2 | Free volume hole size of cyanate ester resin/epoxy resin interpenetrating networks and its correlations with physical properties 显示文摘 | Minfeng Zeng Cuiyun Lu | 2010 | Radiation Physics and Chemistry2010，79，： | 1 |
| 3 | Investigation of free volume and the interra- cial and toughening behavior for epoxy resin/rubber compo- sites by positron annihilation 显示文摘 | Zeng Minfeng | 2008 | Radiation Phys Chem2008，77，： | 1 |
| 4 | Investigation of free volume and the interfacial, and toughening behavior for epoxy resin/rubber composites by positron annihilation显示文摘 | Zeng Minfeng Sun Xudong Xiao Huiquan Ji Genzhong Jiang Xuewen Wang Baoyi Qi Chenze | 2007 | Radiation Physics and Chemistry2007，，3： | 1 |
| 5 | One-step synthesis of carbon functionalized with sulfonic acid groups using hydrothermal carbonization显示文摘 | Xuezheng Liang Minfeng Zeng Chenze Qi | 2010 | Carbon2010，，6： | 1 |
| 6 | Free volume hole size of cyanate es- ter resin/epoxy resin interpenetrating networks and its correlations with physical properties 显示文摘 | Zeng Minfeng | 2010 | Radiation Physics and Chemistry2010，79，9： | 1 |
| 7 | Application of phase dispersion-crosslinking synergism on recycling commingled Plastic wastes 显示文摘 | Fang Zhengping Zeng Minfeng Cai Guoping | 2001 | Appl Polym Sci2001，82，12： | 1 |
| 8 | Free volume hole size of cyanate ester resin / epoxy resin interpenetrating networks and its correlations with physical propertie显示文摘 | Zeng Minfeng Lu Cuiyun Wang Baoyi | 2010 | Radiat Phys Chem2010，79，9： | 1 |
| 9 | Free volume hole size of Cyanate ester resin / Epoxy resin interpenetrating networks and its correlations with physical properties显示文摘 | Zeng Minfeng Lu Cuiyun Wang Baoyi | 2010 | Radiation Physics and Chemistry2010，79，9： | 1 |
| 10 | Free volume hole size of Cyanate ester resin/Epoxy resin interpenetrating networks and its correlations with physical properties显示文摘 | Minfeng Zeng Cuiyun Lu Baoyi Wang Chenze Qi | 2010 | Radiation Physics and Chemistry2010，，9： | 1 |
| 11 | Effect of compatibility on the structure of the microporous membrane prepared by selective dissolution of chitosan/synthetic polymer blend membrane显示文摘 | ZENG Minfeng FANG Zhengping XU Chengwei | 2004 | Journal of Membrane Science2004，230，12： | 1 |
| 12 | Trastuzumab-Induced Severe Thrombocytopenia: A Case Report and Literature Review显示文摘Wie present a 29-year-old woman with pT2N0M0 breast cancer,histological diagnosis of invasive ductal carcinoma,ER and PR low positive,and HER-2(3+).The patient developed trastuzumab-induced thrombocytopenia in 6 hours after an intravenous infusion of trastuzumab at the second cycle of trastuzumab treatment with the symptom of abnormal uterine bleeding.Laboratory exam revealed a sharp drop of platelet count down to 3X109/L.With the treatment of single-donor platelet transfusions,glucocorticoids,oxytocin and thrombopoietic drugs,the platelet count recovered completely in 11 days.This case was confirmed to be severe thrombocytopenia induced by trastuzumab,and retreatment with trastuzumab was not attempted.With increasing clinical utilization of trastuzumab,clinicians are likely to encounter more life-threatening trastuzumab induced severe thrombocytopenia.By this case report and literature review we hope to increase the awareness,attach the attentions to this condition,and help with the effective treatment. | Xiaoqi Zeng Shanshan Jiang Yuanyang Peng Minfeng Liu Changsheng Ye Jianyu Dong | 2020 | Chinese Medical Sciences Journal2020，35，4： | 1 |
| 13 | One-Step Synthesis of Carbon Functionalized with Sulfonic Acid Groups Using Hydrothermal Carbonization显示文摘 | Liang Xuezheng Zeng Minfeng Qi Chenze | 2010 | Carbon2010，48，6： | 1 |
| 14 | The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway显示文摘Osteosarcoma is a kind of bone tumor with highly proliferative and invasive properties,a high incidence of pulmonary metastasis and a poor prognosis.Chemotherapy is the mainstay of treatment for osteosarcoma.Currently,there are no molecular targeted drugs approved for osteosarcoma treatment,particularly effective drugs for osteosarcoma with pulmonary metastases.It has been reported that fibroblast activation protein alpha(FAPa)is upregulated in osteosarcoma and critically associated with osteosarcoma progression and metastasis,demonstrating that FAPa-targeted agents might be a promising therapeutic strategy for osteosarcoma.In the present study,we reported that the FAPa-activated vinblastine prodrug Z-GP-DAVLBH exhibited potent antitumor activities against FAPa-positive osteosarcoma cells in vitro and in vivo.Z-GP-DAVLBH inhibited the growth and induced the apoptosis of osteosarcoma cells.Importantly,it also decreased the migration and invasion capacities and reversed epithelial-mesenchymal transition(EMT)of osteosarcoma cells in vitro and suppressed pulmonary metastasis of osteosarcoma xenografts in vivo.Mechanistically,Z-GP-DAVLBH suppressed the AXL/AKT/GSK-3β/β-catenin pathway,leading to inhibition of the growth and metastatic spread of osteosarcoma cells.These findings demonstrate that Z-GP-DAVLBH is a promising agent for the treatment of FAPa-positive osteosarcoma,particularly osteosarcoma with pulmonary metastases. | Geni Ye Maohua Huang Yong Li Jie Ouyang Minfeng Chen Qing Wen Xiaobo Li Huhu Zeng Pei Long Zepei Fan Junqiang Yin Wencai Ye Dongmei Zhang | 2022 | Acta Pharmaceutica Sinica B2022，12，3： | 1 |
| 15 | Investiga-tion of free volume and the interfacial,and toughening behavior for epoxy resin/rubber composites by positron annihilation显示文摘 | Zeng Minfeng Sun Xudong Xiao Huiquan | 2008 | Radiat Phys Chem2008，77，3： | 1 |
| 16 | Free volume hole size of cyanate ester resin / epoxy resin interpenetrating networks and its correlations with physical properties显示文摘 | Zeng Minfeng Lu Cuiyun Wang Baoyi | 2010 | Radiation Physics and Chemistry2010，79，9： | 1 |
| 17 | Free volume hole size of cyanate ester resin/ep- oxy resin interpenetrating networks and its correlations with physical properties显示文摘 | Zeng Minfeng | 2010 | Radiation Physics and Chemistry2010，79，9： | 1 |
| 18 | Author correction to“The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway”[Acta Pharm Sin B 12(2022)1288–1304]显示文摘We deeply regret that the representative image of invaded 143B cells treated with Z-GP-DAVLBH + AXL-KD in the lower panel of Fig. 6C was incorrect due to inadvertent mistake of copying and pasting in the process of assembling figures with Adobe Illustrator software. The image has now been corrected, and the quantification of cell invasion in Fig. 6C remains correct. The corrected version of Fig. 6C has been provided below, and the change did not affect the results and conclusions of this study. We have provided the original data of this figure to Editorial Office, and the Editorial Office or the corresponding authors can be contacted for original data access. | Geni Ye Maohua Huang Yong Li Jie Ouyang Minfeng Chen Qing Weng Xiaobo Li Huhu Zeng Pei Long Zepei Fan Junqiang Yin Wencai Ye Dongmei Zhang | 2023 | Acta Pharmaceutica Sinica B2023，13，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员